X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2355) 2355
Publication (325) 325
Book Review (34) 34
Book Chapter (14) 14
Book / eBook (6) 6
Conference Proceeding (5) 5
Dissertation (2) 2
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1620) 1620
humans (1527) 1527
animals (1071) 1071
male (1029) 1029
female (684) 684
clopidogrel (602) 602
ticlopidine - analogs & derivatives (568) 568
purinergic p2y receptor antagonists - administration & dosage (484) 484
middle aged (472) 472
adenosine - analogs & derivatives (446) 446
aged (422) 422
atp (422) 422
purinergic p2y receptor antagonists - therapeutic use (419) 419
cardiac & cardiovascular systems (418) 418
neurosciences (416) 416
platelet aggregation inhibitors - administration & dosage (406) 406
rats (404) 404
platelet aggregation inhibitors - therapeutic use (392) 392
pharmacology & pharmacy (378) 378
treatment outcome (365) 365
percutaneous coronary intervention (348) 348
ticagrelor (341) 341
purinergic p2y receptor antagonists - adverse effects (325) 325
prasugrel (317) 317
acute coronary syndromes (313) 313
mice (304) 304
platelet aggregation inhibitors - adverse effects (299) 299
dose-response relationship, drug (278) 278
platelet aggregation - drug effects (278) 278
blood platelets - drug effects (277) 277
ticlopidine - administration & dosage (269) 269
purinergic p2 receptor antagonists (261) 261
adenosine triphosphate - pharmacology (258) 258
ticlopidine - therapeutic use (257) 257
receptors, purinergic p2 - metabolism (254) 254
aspirin (251) 251
acute coronary syndrome - drug therapy (247) 247
prasugrel hydrochloride (245) 245
adenosine (243) 243
purinergic p2y receptor antagonists - pharmacology (241) 241
time factors (236) 236
abridged index medicus (226) 226
platelet aggregation inhibitors - pharmacology (224) 224
adenosine - administration & dosage (213) 213
adenosine triphosphate - metabolism (207) 207
rats, sprague-dawley (206) 206
hematology (199) 199
risk factors (199) 199
peripheral vascular disease (198) 198
cardiovascular (188) 188
adenosine - therapeutic use (187) 187
inhibition (187) 187
antiplatelet therapy (185) 185
analysis (184) 184
p2y (184) 184
adult (181) 181
blood platelets - metabolism (179) 179
drug therapy, combination (178) 178
hemorrhage - chemically induced (171) 171
ticlopidine - adverse effects (171) 171
prospective studies (170) 170
platelet function tests (168) 168
purinergic receptors (165) 165
acute coronary syndrome (164) 164
care and treatment (164) 164
physiology (162) 162
thrombosis (161) 161
adenosine triphosphate - analogs & derivatives (160) 160
inflammation (159) 159
cell biology (157) 157
activation (156) 156
coronary heart disease (156) 156
extracellular atp (156) 156
signal transduction (155) 155
receptors, purinergic p2 - physiology (154) 154
blood platelets (149) 149
cardiac patients (149) 149
aspirin - therapeutic use (147) 147
receptors (145) 145
p2x receptors (144) 144
adenosine - adverse effects (141) 141
aspirin - administration & dosage (140) 140
myocardial-infarction (140) 140
biomedicine (139) 139
cardiology (139) 139
drug therapy (138) 138
heart attacks (138) 138
physiological aspects (137) 137
disease models, animal (136) 136
research (134) 134
ticlopidine - pharmacology (133) 133
neurons (132) 132
cells, cultured (131) 131
adenosine - pharmacology (129) 129
platelets (123) 123
administration, oral (122) 122
platelet activation - drug effects (121) 121
article (120) 120
platelet inhibition (119) 119
thiophenes - administration & dosage (119) 119
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2335) 2335
Italian (7) 7
French (6) 6
German (6) 6
Russian (6) 6
Chinese (2) 2
Danish (1) 1
Hungarian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Circulation, ISSN 0009-7322, 11/2010, Volume 122, Issue 21, pp. 2131 - 2141
Background-Aspirin and clopidogrel are recommended for patients with acute coronary syndromes (ACS) or undergoing coronary stenting. Ticagrelor, a reversible... 
acute coronary syndrome | thrombosis | platelets | myocardial infarction | hemorrhage | 2007 FOCUSED UPDATE | AZD6140 | CARDIAC & CARDIOVASCULAR SYSTEMS | SEGMENT ELEVATION | MANAGEMENT | EVENTS | P2Y RECEPTOR ANTAGONIST | ASPIRIN | ACUTE MYOCARDIAL-INFARCTION | DOUBLE-BLIND | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | ASSOCIATION | Purinergic P2Y Receptor Antagonists - administration & dosage | Coronary Thrombosis - epidemiology | Humans | Middle Aged | Male | Angioplasty, Balloon, Coronary | Purinergic P2Y Receptor Antagonists - adverse effects | Adenosine - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Coronary Thrombosis - prevention & control | Ticlopidine - adverse effects | Electrocardiography | Ticlopidine - administration & dosage | Female | Platelet Aggregation Inhibitors - adverse effects | Acute Coronary Syndrome - epidemiology | Hemorrhage - epidemiology | Risk Factors | Kaplan-Meier Estimate | Treatment Outcome | Adenosine - administration & dosage | Ticlopidine - analogs & derivatives | Acute Coronary Syndrome - drug therapy | Adenosine - analogs & derivatives | Acute Coronary Syndrome - diagnosis | Aged | Hemorrhage - chemically induced | Usage | Angioplasty | Patient outcomes | Clopidogrel | Drug therapy | Ticagrelor | Health aspects | Heart attack | Medical and Health Sciences | Medicin och hälsovetenskap | MEDICIN | MEDICINE
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2014, Volume 371, Issue 11, pp. 1016 - 1027
This study compared administration of the antiplatelet agent ticagrelor in the ambulance with administration in the cath lab in patients with ST-segment... 
MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | GLYCOPROTEIN IIB/IIIA INHIBITORS | CLOPIDOGREL | MANAGEMENT | INITIATION | PLATELET INHIBITION | DOUBLE-BLIND | IIB-IIIA INHIBITORS | PRASUGREL | PRIMARY ANGIOPLASTY | Myocardial Infarction - mortality | Purinergic P2Y Receptor Antagonists - administration & dosage | Humans | Middle Aged | Male | Purinergic P2Y Receptor Antagonists - adverse effects | Adenosine - adverse effects | Ticlopidine - adverse effects | Ticlopidine - administration & dosage | Female | Drug Therapy, Combination | Myocardial Infarction - diagnosis | Double-Blind Method | Time-to-Treatment | Anticoagulants - therapeutic use | Electrocardiography - drug effects | Adenosine - administration & dosage | Anticoagulants - adverse effects | Ticlopidine - analogs & derivatives | Coronary Angiography | Myocardial Infarction - drug therapy | Myocardial Reperfusion | Adenosine - analogs & derivatives | Aged | Hemorrhage - chemically induced | Emergency Medical Services | Administration | Care and treatment | Hospitals | Research | Management | Heart attack | Risk factors | Myocardial infarction | Heart attacks | Catheterization | Angiography | Clinical trials | Patients | Thrombosis | Thrombolysis | Bleeding | Clinical outcomes | Studies | Reperfusion | Blood platelets | Coronary vessels | Implants | Intubation | Acute coronary syndromes | Drug therapy | Infart de miocardi | Adenosine | Malalties coronàries | Anticoagulants (Medicine) | Anticoagulants (Medicina) | Adenosina | Coronary diseases | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2015, Volume 372, Issue 19, pp. 1791 - 1800
Patients with myocardial infarction 1 to 3 years previously were assigned to ticagrelor, 90 or 60 mg twice daily, or to placebo, in addition to low-dose... 
MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | CLOPIDOGREL | MANAGEMENT | ESC GUIDELINES | AMERICAN-COLLEGE | PREVENTION | ASSOCIATION TASK-FORCE | ACUTE CORONARY SYNDROMES | PRASUGREL | ASPIRIN | Purinergic P2Y Receptor Antagonists - administration & dosage | Double-Blind Method | Drug Administration Schedule | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Risk | Secondary Prevention | Adenosine - administration & dosage | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Myocardial Infarction - drug therapy | Adenosine - adverse effects | Adenosine - analogs & derivatives | Intracranial Hemorrhages - chemically induced | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Aged | Hemorrhage - chemically induced | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Dose-response relationship (Biochemistry) | Treatment outcome | Care and treatment | Safety and security measures | Analysis | Dosage and administration | Ticagrelor | Heart attack | Risk factors | Myocardial infarction | Cerebral infarction | Aspirin | Stroke | Heart attacks | Hemorrhage | Long term | Patients | Thrombolysis | Bleeding | Blood platelets | Antagonist drugs | Cardiovascular diseases | Drug therapy | Life Sciences | Human health and pathology
Journal Article
Nature Reviews Cardiology, ISSN 1759-5002, 01/2016, Volume 13, Issue 1, pp. 11 - 27
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2013, Volume 369, Issue 11, pp. 999 - 1010
Journal Article